Santhera Pharmaceuticals

📍 Pratteln, Switzerland🗓 Founded 2004👥 70 employees💰 Last funded 2004
Pharmaceutical Manufacturing🌐 santhera.com
Website LinkedIn
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. Santhera out-licensed rights to its first approved product, Raxone® (idebenone), outside North America and France for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For more information, please visit the Company's website at www.santhera.com
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2004
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Santhera Pharmaceuticals?
Santhera Pharmaceuticals has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Santhera Pharmaceuticals last raise funding?
The most recent investment in Santhera Pharmaceuticals recorded on gritt.io was in 2004.
When was Santhera Pharmaceuticals founded?
Santhera Pharmaceuticals was founded in 2004.
What industry is Santhera Pharmaceuticals in?
Santhera Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Santhera Pharmaceuticals based?
Santhera Pharmaceuticals is headquartered in Pratteln, Switzerland.